Skip to content
Pataday twice daily relief, Opatanol(olopatadine)
Opatanol, Pataday, Ryaltris (olopatadine) is a small molecule pharmaceutical. Olopatadine was first approved as Pataday twice daily relief on 1996-12-18. It is used to treat allergic conjunctivitis in the USA. It has been approved in Europe to treat allergic conjunctivitis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
immune system diseasesD007154
Trade Name
FDA
EMA
Pataday (generic drugs available since 2014-10-08, discontinued: Patanase)
Combinations
Ryaltris
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mometasone furoate
+
Olopatadine hydrochloride
Tradename
Company
Number
Date
Products
RYALTRISGlenmark PharmaceuticalsN-211746 RX2022-01-13
1 products, RLD, RS
Olopatadine hydrochloride
Tradename
Company
Number
Date
Products
PATADAY TWICE DAILY RELIEFAlcon ResearchN-020688 OTC1996-12-18
1 products, RLD, RS
PATADAY ONCE DAILY RELIEFAlcon ResearchN-021545 OTC2004-12-22
1 products, RLD, RS
PATADAY ONCE DAILY RELIEFAlcon ResearchN-206276 OTC2015-01-30
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
olopatadine hydrochlorideANDA2023-06-07
pataday once daily reliefNew Drug Application2020-12-19
patanaseNew Drug Application2022-07-13
ryaltrisNew Drug Application2022-01-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic conjunctivitisEFO_0007141D003233H10.44
Agency Specific
FDA
EMA
Expiration
Code
MOMETASONE FUROATE / OLOPATADINE HYDROCHLORIDE, RYALTRIS, GLENMARK SPECIALTY
2025-01-13NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Mometasone Furoate / Olopatadine Hydrochloride, Ryaltris, Glenmark Specialty
90789232034-09-04DPU-3297
93704832034-09-04DP
97507542034-09-04DPU-3297
99371892034-09-04DP
100164432034-09-04U-3297
103765262034-09-04DP
105178802034-09-04DPU-3297
105489072034-09-04U-3297
105616722034-09-04DP
106465002034-09-04U-3297
107585502034-09-04U-3296
107656862034-09-04U-3295
114001012034-09-04U-3297
Olopatadine Hydrochloride, Pataday Once Daily Relief, Alcon Labs Inc
87911542032-05-19DPU-1680
95330532032-05-19DP
Olopatadine Hydrochloride, Patanase, Novartis
79773762023-02-02DP
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AC: Antiallergic nasal preparations for topical use, excl. corticosteroids
— R01AC08: Olopatadine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GX: Other antiallergics in atc
— S01GX09: Olopatadine
HCPCS
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic conjunctivitisD003233EFO_0007141H10.44141219238
Allergic rhinitis seasonalD006255EFO_0003956J30—243—9
Allergic rhinitisD065631J30.9—1—214
Allergic rhinitis perennialD012221EFO_1001417J30.89——21—3
Vasomotor rhinitisD012223EFO_0007533J30.0———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypersensitivityD006967EFO_0003785T78.40——2——2
ConjunctivitisD003231H10——2——2
RhinitisD012220EFO_0008521J31——2——2
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOLOPATADINE
INNolopatadine
Description
Olopatadine is a dibenzooxazepine.
Classification
Small molecule
Drug classtricyclic histaminic-H1 receptor antagonists, loratadine derivatives (formerly-tadine)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21
Identifiers
PDB—
CAS-ID113806-05-6
RxCUI—
ChEMBL IDCHEMBL1189432
ChEBI ID—
PubChem CID5284599
DrugBankDB00768
UNII IDD27V6190PM (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Olopatadine - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 797 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details